If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
14 June 2018 The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.
21 December 2017 Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.
14 June 2018 The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.
21 December 2017 Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.
14 June 2018 The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.
21 December 2017 Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.